Slide 1: Median Technologies Cowen Presentation
Median Technologies Cowen Presentation March 13, 2018
Slide 2: Disclaimer
Disclaimer ▪ Median Technologies, its directors, officers, advisors and employees make no representation or warranty as to statistical data or predictions contained in this presentation that were taken or derived from third party sources or industry publications; such statistical data and forecasts
Slide 3: Our Mission: Transforming imaging data into clinical information
Our Mission: Transforming imaging data into clinical information Applying medicine, cloud computing, artificial intelligence to imaging technology to revolutionize the way drugs are developed and medical care is delivered Leading technology company applying Artificial Intelligence for non-invasive i
Slide 4: Mapping the Phenotype
Mapping the Phenotype Select patients for clinical trials Monitor patients under treatment Patient selection for targeted therapies Screening and early detection of cancers and other chronic diseases Predict treatment response Predict patient prognosis or outcome
Slide 5: Slide 5
Slide 6: Applying imaging phenomics to the patient journey
Applying imaging phenomics to the patient journey Clinical Trials Patient Care THE MARKET Optimize the assessment of new Improve the screening, diagnosis, drugs in clinical trials monitoring of patients and determine treatment effectiveness SOLUTIONS
Slide 7: Configurable technology system with computer-assisted lesion detection
Configurable technology system with computer-assisted lesion detection and identification – to accelerate start-up, reduce errors and ensure data accuracy for clinical trials; addressing a ~$1b oncology clinical trials market Pulmonary nodule volume Lesion density assessment Liver lesion RECIST asse
Slide 8: Automated clinical technology for lung cancer screening
Automated clinical technology for lung cancer screening to transform identification and management of lesions – easy to use in reducing false positives and improving patient care addressing a ~$500m lung cancer market
Slide 9: Accelerate growth with dedicated focus
Accelerate growth with dedicated focus 2017 Financial Highlights¹ Focus Improvements 21% Revenue growth to €7.69m People €14.7m Net new business 23% Backlog increase to €23m indicating future revenue growth €28.3m Cash and cash equivalents Process Technology ¹As of Dec 31, 2017, Unaudited. Full Audi
Slide 10: Driving new business for continued growth
Driving new business for continued growth Basis point increase on our new 15 business win conversion rate New preferred-provider relationships, including the world’s 16 largest biotech with differentiated products in oncology >85 Studies with ~25% studies coming from top 20 pharmaceutical companies
Slide 11: …fueled by innovation and collaboration
…fueled by innovation and collaboration Best-in-class partnerships with top pharma, CROs and hospitals Several top 10 Pharmaceutical
Slide 12: Operational excellence, innovation and new business to guide continued growth
Operational excellence, innovation and new business to guide continued growth Revenue €7.69 Value in Millions €.07 €6.35 €7.61 €.14 For iCRO (iSee®) business, Median Technologies expects to deliver a 20-25% CAGR for the next three €6.22 €3.89 years €.15 €3.74 For iCRO (iSee®) business, Median Techno
Slide 13: Continued focus to drive growth
Continued focus to drive growth 2018 strategic imperatives: Develop additional strategic partnerships Increase backlog for iCRO (iSee®) Scale MediScan® Execute on clinical validation and partnering strategy for iBiopsy® Continue the growth story
Slide 14: Trends transforming the industry
Trends transforming the industry Making medicine predictive, personalized, pre-emptive and participatory ~2,314 exabytes of HC data will be produced in 20201 Big Patient-level –omics data and AI Data will enable personalized treatment Personalized Cloud Medicine Computing Multi-omics data integrated
Slide 15: Personalized medicine and prediction; drug development; clinical decision support
Personalized medicine and Drug development and Clinical decision 1 2 3 Clinical decision support support prediction treatment response Aerts et al. Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860
Slide 16: AI applied to cancer diagnosis
AI applied to cancer diagnosis
Slide 17: Continuing to innovate
Continuing to innovate 2018 Roadmap With key partners Q2: NASH study results Prostate cancer Cloud computing; (May) encryption Q2: Prostate study results (June) Lung cancer NASH disease Q2 - Q3: Lung study results (April, June, September) + Top 10 Pharmaceutical Q4: Lung FDA 510(k) submission
Slide 18: Median Technologies
Median Technologies Consistent focus on process An attractive investment and productivity leverage Long-term consistent financial performance Diverse revenue base Serving an attractive and growing market Deep and diverse customer Leader in Imaging Phenomics relationships comprised of top pharma, mid
Slide 19: Management Team
Median Technologies Management Team Fredrik Brag Jeanne Hecht Nick Campbell Bernard Reymann James Golando CEO, Chairman and Chief Operating Officer Chief Commercial Officer Chief Financial Officer Chief of Operations Co-founder Loan Hoang-Sayag Peter Bannister Margie Kooman Chief Medical Officer Chi
Slide 20: median
median